A transmembrane domain-derived peptide inhibits D1 dopamine receptor function without affecting receptor...

Area of Science:

• Pharmacology
• Neuroscience
• Molecular Biology

Background:

• G protein-coupled receptors (GPCRs) play crucial roles in cellular signaling.
• The D1 dopamine receptor (D1DR) is a key GPCR involved in various neurological processes.
• Previous studies showed peptides from other receptors can disrupt dimerization and function.

Purpose of the Study:

• To investigate the effect of a peptide based on D1DR transmembrane domain 6 on D1DR binding and function.
• To determine if this peptide affects D1DR oligomerization.
• To explore the potential of this peptide as a novel D1DR antagonist.

Main Methods:

• Synthesized a peptide based on D1DR transmembrane domain 6.
• Assessed the peptide's effect on D1DR antagonist binding using dose-dependent inhibition assays.
• Measured dopamine-induced GTPgammaS binding and adenylyl cyclase activity.
• Analyzed D1DR oligomeric states using immunoblotting.

Main Results:

• The D1DR transmembrane 6 peptide caused dose-dependent, irreversible inhibition of antagonist binding.
• This peptide attenuated dopamine-induced GTPgammaS binding and adenylyl cyclase activity below baseline.
• Receptor oligomeric states (monomers, dimers, higher-order oligomers) remained unaffected by the peptide.
• Peptides from other GPCR transmembrane domains did not show similar effects on D1DR.

Conclusions:

• A peptide derived from D1DR transmembrane 6 specifically inhibits D1DR binding and function.
• This inhibition occurs without affecting receptor oligomerization.
• The findings suggest a novel class of noncompetitive D1DR antagonists based on transmembrane 6 peptides.
• This approach may offer new therapeutic strategies for conditions involving D1DR signaling.